Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
- Resource Type
- Article
- Source
- The Lancet; January 2024, Vol. 403 Issue: 10422 p171-182, 12p
- Subject
- Language
- ISSN
- 01406736; 1474547X